Pulmonary Arterial Hypertension (PAH) Market size is set to surpass USD 10.1 billion by 2027, according to a new research report by Global Market Insights Inc.
Growing investments in research activities related to pulmonary arterial hypertension has led to the development of strong product pipeline, further driving the market growth. The studies emphasizing on assessing the pathogenesis and pathophysiology of pulmonary arterial hypertension have evolved in the recent years. Renewed interest in development of novel drugs through collaborations between major industry players as well as regulatory agencies is further expected to promote the pulmonary arterial hypertension market expansion.
Prominent leaders are partnering for accelerating the development of effective therapeutics to aid the pulmonary arterial hypertension management. The ongoing efforts associated with identification of novel pathogenic pathways and adopting rigorous clinical trial designs to complement the robust R&D initiatives are anticipated to bolster the pulmonary arterial hypertension drugs pipeline and, thereby augmenting the market progression in the coming years.
Increasing prevalence of pulmonary arterial hypertension is poised to fuel the market demand during the forecast timeline. According to the BMC Nephrology 2020 article, the prevalence of pulmonary arterial hypertension in a cross sectional study in Democratic Republic of Congo was estimated to be around 29.4%. People suffering with PAH are further associated with higher incidence of co-morbidities such as hyponatremia, arrhythmia, vascular access change and diastolic dysfunction among others. Recent data from the U.S. and Europe demonstrate that PAH is now commonly detected in elderly patients along with presence of host of cardiovascular comorbidities.
Several advantages associated with the use of vasodilators in severe PAH patients is predicted to spur the pulmonary arterial hypertension market value
Get more details on this report - Request Free Sample PDF
The vasodilators segment was valued at around USD 1.36 billion in 2020 led by the increased survival chances in critical patients with the use of vasodilators. Pulmonary vasodilators such as endothelin, nitric oxide, and prostacyclin target and modulate the disease causing PAH pathways. These drugs majorly address the vasoconstrictive phenotype of PAH that is the predominant feature in patients deemed as vasoresponders. Vasodilator are associated with notable increase in exercise capacity, better quality of life, and reduced morbidity. Moreover, these drugs limit pulmonary artery pressure, enhance hemodynamic function, promote exercise tolerance, and increase the survival chances in patients suffering from severe PAH.
Browse key industry insights spread across 120 pages with 130 market data tables & 13 figures & charts from the report, “Pulmonary Arterial Hypertension Market Size By Drug Class (Prostacyclin And Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators, Endothelin Receptor Antagonist (ERA), Phosphodiesterase 5 (PDE-5), Vasodilators), By Route of Administration (Oral, Intravenous, Inhalation), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027” in detail along with the table of contents:
Fast-acting and effective mode of drug administration provided by intravenous therapy will expand the existing customer pool
The pulmonary arterial hypertension market for intravenous segment is slated to reach USD 1.55 billion by 2027 owing to the fast-acting and effective mode of drug administration provided by intravenous therapy. This therapy is prescribed for patients that witness challenging circumstances related to oral intake of medications. Intravenous medical therapy in PAH had been linked with improvising clinical outcomes, increasing the survival chances, functional status, and quality of life.
Furthermore, availability of several approved drugs for intravenous therapy have shown promising outcomes in the recent years that will surge the demand for these medications. Recommended drugs for intravenous PAH therapy such as epoprostenol, macitentan, ambrisentan, sildenafil, and tadalafil among others are available in the market. Intravenous epoprostenol treatment is recommended for PAH class 1 patients as per the European Society of Cardiology and European Respiratory Society guidelines.
Growing prevalence of pulmonary arterial hypertension in China is projected to propel the industry growth
China pulmonary arterial hypertension market held a significant revenue share in the APAC region and is anticipated to expand at 5.3% growth rate through 2027 on account of the increasing prevalence of PAH and aging population. The rising prevalence of PAH along with associated co-factors such as congenital heart disease (CHD) PAH, systemic lupus erythematosus (SLE) PAH and idiopathic/heritable PAH in China will promote the demand for PAH medications further fostering the market revenue. As per the World Health Organization (WHO), the congenital heart disease associated with PAH is predominant in China and attributed to limited access to cardiac surgical procedures. The PAH majorly affects elderly adults and soaring geriatric population in the country will accelerate the industry expansion.
Players are focusing on implementing strategic initiatives such as product commercialization to expand the business operations
Some of the major companies operating in the pulmonary arterial hypertension market are Bayer AG, Eli Lilly & Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc. and United Therapeutics Corporation. These participants are engaged in strategic collaborations, vertical integration, product launches, research partnerships and distribution agreements to gain competitive advantage over their competitors and capture maximum market share.
Explore More on Related Topics: